Published in Neurotoxicology on September 03, 1999
Manganese and Parkinson's disease: a critical review and new findings. Environ Health Perspect (2010) 1.66
Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. J Neurochem (2008) 1.31
Manganese neurotoxicity: lessons learned from longitudinal studies in nonhuman primates. Environ Health Perspect (2008) 1.19
Mechanisms of lead and manganese neurotoxicity. Toxicol Res (Camb) (2013) 1.09
Inhibition of DAT function attenuates manganese accumulation in the globus pallidus. Environ Toxicol Pharmacol (2007) 1.01
Manganese homeostasis in the nervous system. J Neurochem (2015) 0.98
Genetic factors and manganese-induced neurotoxicity. Front Genet (2014) 0.90
Iron-responsive olfactory uptake of manganese improves motor function deficits associated with iron deficiency. PLoS One (2012) 0.90
α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease. Toxicol Sci (2014) 0.88
Manganese exposure alters extracellular GABA, GABA receptor and transporter protein and mRNA levels in the developing rat brain. Neurotoxicology (2008) 0.86
Chronic exposure to manganese alters brain responses to amphetamine: a pharmacological magnetic resonance imaging study. Toxicol Sci (2010) 0.80
p73 gene in dopaminergic neurons is highly susceptible to manganese neurotoxicity. Neurotoxicology (2016) 0.75
RNASeq in C. elegans Following Manganese Exposure. Curr Protoc Toxicol (2015) 0.75
Manganese inhalation as a Parkinson disease model. Parkinsons Dis (2010) 0.75
Arsenic: health effects, mechanisms of actions, and research issues. Environ Health Perspect (1999) 3.07
DMSA and DMPS--water soluble antidotes for heavy metal poisoning. Annu Rev Pharmacol Toxicol (1983) 1.76
Monomethylarsonous acid (MMA(III)) and arsenite: LD(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem Res Toxicol (2001) 1.72
Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. Chem Res Toxicol (2001) 1.65
Speciation of key arsenic metabolic intermediates in human urine. Anal Chem (2000) 1.65
Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ Health Perspect (2000) 1.58
Pharmacokinetics of meso-2,3-dimercaptosuccinic acid in patients with lead poisoning and in healthy adults. J Pediatr (1994) 1.58
Choroid plexus protects cerebrospinal fluid against toxic metals. FASEB J (1991) 1.27
Enzymatic methylation of arsenic compounds: assay, partial purification, and properties of arsenite methyltransferase and monomethylarsonic acid methyltransferase of rabbit liver. Chem Res Toxicol (1995) 1.26
Rabbit muscle creatine phosphokinase. CDNA cloning, primary structure and detection of human homologues. J Biol Chem (1984) 1.24
Glossopharyngeal neuralgia with syncope secondary to tumor. Treatment and pathophysiology. Am J Med (1981) 1.20
Physician-scientists at risk. Science (1999) 1.16
The enigma of arsenic carcinogenesis: role of metabolism. Toxicol Sci (1999) 1.16
Deep brain stimulation in epilepsy. J Clin Neurophysiol (2001) 1.15
Neurobehavioral effects from exposure to dental amalgam Hg(o): new distinctions between recent exposure and Hg body burden. FASEB J (1998) 1.10
N-(2,3-dimercaptopropyl)phthalamidic acid (DMPA) increases polonium-210 excretion. Biol Met (1990) 1.07
DNA and gene therapy: uncoating of polyoma pseudovirus in mouse embryo cells. Proc Natl Acad Sci U S A (1970) 1.04
Enzymatic reduction of arsenic compounds in mammalian systems: the rate-limiting enzyme of rabbit liver arsenic biotransformation is MMA(V) reductase. Chem Res Toxicol (1999) 1.04
A deoxyribonuclease found after infection of Bacillus subtilis with phage SP3. Proc Natl Acad Sci U S A (1965) 1.04
Enzymatic methylation of arsenic compounds. III. The marmoset and tamarin, but not the rhesus, monkeys are deficient in methyltransferases that methylate inorganic arsenic. Toxicol Appl Pharmacol (1996) 1.02
DNA and gene therapy: transfer of mouse DNA to human and mouse embryonic cells by polyoma pseudovirions. Proc Natl Acad Sci U S A (1971) 1.02
Formation of nucleoprotein complexes between polyoma empty capsides and DNA. J Virol (1975) 1.01
Determination and metabolism of dithiol chelating agents. XVI: Pharmacokinetics of 2,3-dimercapto-1-propanesulfonate after intravenous administration to human volunteers. J Pharmacol Exp Ther (1994) 0.98
Determination and metabolism of dithiol chelating agents. XII. Metabolism and pharmacokinetics of sodium 2,3-dimercaptopropane-1-sulfonate in humans. J Pharmacol Exp Ther (1991) 0.97
Enzymatic reduction of arsenic compounds in mammalian systems: reduction of arsenate to arsenite by human liver arsenate reductase. Chem Res Toxicol (2000) 0.97
Central nervous system toxicity of manganese. I. Inhibition of spontaneous motor activity in rats after intrathecal administration of manganese chloride. Fundam Appl Toxicol (1995) 0.96
Structural basis of the antagonism between inorganic mercury and selenium in mammals. Chem Res Toxicol (2000) 0.96
Enzymatic methylation of arsenic compounds. VII. Monomethylarsonous acid (MMAIII) is the substrate for MMA methyltransferase of rabbit liver and human hepatocytes. Toxicol Appl Pharmacol (1999) 0.95
The deoxycytidylate deaminase found in Bacillus subtilis infected with phage SP8. Biochemistry (1967) 0.95
Deoxythymidylate 5'-nucleotidase. Purification and properties of an enzyme found after infection of Bacillus subtilis with phage SP5C. J Biol Chem (1966) 0.94
Polyoma pseudovirions. I. Sequence of events in primary mouse embryo cells leading to pseudovirus production. J Virol (1972) 0.93
Arsenite methylation by methylvitamin B12 and glutathione does not require an enzyme. Toxicol Appl Pharmacol (1999) 0.92
Determination and metabolism of dithiol chelating agents. XV. The meso-2,3-dimercaptosuccinic acid-cysteine (1:2) mixed disulfide, a major urinary metabolite of DMSA in the human, increases the urinary excretion of lead in the rat. J Pharmacol Exp Ther (1993) 0.91
Arsenic binding proteins of mammalian systems: I. Isolation of three arsenite-binding proteins of rabbit liver. Toxicology (1994) 0.91
Determination and metabolism of dithiol chelating agents: X. In humans, meso-2,3-dimercaptosuccinic acid is bound to plasma proteins via mixed disulfide formation. J Pharmacol Exp Ther (1990) 0.91
Proximal limb movements in response to microstimulation of primate dentate and interpositus nuclei mediated by brain-stem structures. Brain (1979) 0.90
Health helpers in Erie County, N.Y. HSMHA Health Rep (1971) 0.90
Behavioral effects of low-level exposure to Hg0 among dental professionals: a cross-study evaluation of psychomotor effects. Neurotoxicol Teratol (1998) 0.89
A longitudinal study of neuropsychological change in individuals with Parkinson's disease. Int J Geriatr Psychiatry (2003) 0.89
Comparing the difficulty of letter, semantic, and name fluency tasks for normal elderly and patients with Parkinson's disease. Neuropsychology (1997) 0.88
Fluorometric determination of 2,3-dimercaptopropane-1-sulfonic acid and other dithiols by precolumn derivatization with bromobimane and column liquid chromatography. J Chromatogr (1986) 0.88
DMSA, DMPS, and DMPA--as arsenic antidotes. Fundam Appl Toxicol (1984) 0.87
Determination and metabolism of dithiol chelating agents. VIII. Metal complexes of meso-dimercaptosuccinic acid. Toxicol Appl Pharmacol (1989) 0.87
Issues in the early diagnosis of Parkinson's disease. Neurology (1997) 0.86
Cell-free assembly of a polyoma-like particle from empty capsids and DNA. Virology (1979) 0.86
Monomethylarsonic acid reductase and monomethylarsonous acid in hamster tissue. Chem Res Toxicol (2000) 0.86
Protection of mice against the lethal effects of sodium arsenite by 2,3 dimercapto-1-propane-sulfonic acid and dimercaptosuccinic acid. Biochem Biophys Res Commun (1980) 0.86
Modeling the effects of Deep Brain Stimulation on sensorimotor cortex in normal and MPTP conditions. Conf Proc IEEE Eng Med Biol Soc (2010) 0.85
Determination and metabolism of dithiol chelating agents. XVII. In humans, sodium 2,3-dimercapto-1-propanesulfonate is bound to plasma albumin via mixed disulfide formation and is found in the urine as cyclic polymeric disulfides. J Pharmacol Exp Ther (1996) 0.85
Determination and metabolism of dithiol chelating agents. VII. Biliary excretion of dithiols and their interactions with cadmium and metallothionein. Fundam Appl Toxicol (1990) 0.85
Diversity of inorganic arsenite biotransformation. Biol Trace Elem Res (1999) 0.83
Sodium 2,3-dimercaptopropane-1-sulfonate challenge test for mercury in humans. III. Urinary mercury after exposure to mercurous chloride. J Pharmacol Exp Ther (1996) 0.83
Enzymatic methylation of arsenic compounds. VI. Characterization of hamster liver arsenite and methylarsonic acid methyltransferase activities in vitro. Toxicol Appl Pharmacol (1998) 0.83
The use of DNA for gene therapy--the need, experimental approach, and implications. Perspect Biol Med (1970) 0.83
DMPS (2,3-dimercaptopropane-1-sulfonate, dimaval) decreases the body burden of mercury in humans exposed to mercurous chloride. J Pharmacol Exp Ther (1998) 0.83
Modeling the motor striatum under Deep Brain Stimulation in normal and MPTP conditions. Conf Proc IEEE Eng Med Biol Soc (2010) 0.83
Polyoma pseudovirions. II. Influence of host cell on pseudovirus production. J Virol (1973) 0.83
Enzymatic methylation of arsenic compounds: IV. In vitro and in vivo deficiency of the methylation of arsenite and monomethylarsonic acid in the guinea pig. Mutat Res (1997) 0.83
Determination and metabolism of dithiol-chelating agents: electrolytic and chemical reduction of oxidized dithiols in urine. Anal Biochem (1987) 0.82
Biological chelation: 2,3-dimercapto-propanesulfonic acid and meso-dimercaptosuccinic acid. Adv Enzyme Regul (1982) 0.81
Protection of mice against lethal effects of sodium arsenite--a quantitative comparison of a number of chelating agents. Toxicol Appl Pharmacol (1981) 0.81
Determination and metabolism of dithiol chelating agents. VI. Isolation and identification of the mixed disulfides of meso-2,3-dimercaptosuccinic acid with L-cysteine in human urine. Toxicol Appl Pharmacol (1989) 0.81
Polyoma-like particle: characterization of the DNA encapsidated in vitro by polyoma empty capsids. J Biol Chem (1982) 0.81
Evaluation of Drosophila melanogaster as an alternative animal for studying the neurotoxicity of heavy metals. Biometals (1992) 0.80
The synthesis and breakdown of nucleic acids in mammalian cells transformed by oncogenic viruses. I. Purification and properties of an endonuclease from baby hamster kidney cells transformed by polyoma virus. J Biol Chem (1970) 0.80
Change in cognitive function in idiopathic Parkinson disease. Arch Neurol (1996) 0.80
Sequential cleavage of dinucleotides from DNA by phage Sp3 DNAse. Proc Natl Acad Sci U S A (1968) 0.79
Generative naming in Parkinson disease patients. J Clin Exp Neuropsychol (1993) 0.79
Sodium 2,3-dimercapto-1-propanesulfonate (DMPS) treatment does not redistribute lead or mercury to the brain of rat. Toxicology (1996) 0.79
The polyoma pseudovirion--its properties, production, and use in transferring DNA to mouse and human cells. Johns Hopkins Med J Suppl (1973) 0.79
Head restraint device for chronic recording of neural activity in the awake monkey. J Neurosci Methods (1988) 0.79
Gender differences in language of Alzheimer disease patients revisited. Alzheimer Dis Assoc Disord (1999) 0.79
Anti-lewisite activity and stability of meso-dimercaptosuccinic acid and 2,3-dimercapto-1-propanesulfonic acid. Life Sci (1982) 0.78
BAL increases the arsenic-74 content of rabbit brain. Toxicol Appl Pharmacol (1983) 0.78
Degradation of pseudoviral DNA after infection of mouse cells with polyoma pseudovirions. Proc Natl Acad Sci U S A (1974) 0.78
Performance on the PD test battery by relatives of patients with progressive supranuclear palsy. Neurology (2001) 0.77
Determination and metabolism of dithiol chelating agents. IV. Urinary excretion of meso-2,3-dimercaptosuccinic acid and mercaptosuccinic acid in rabbits given meso-2,3-dimercaptosuccinic acid. Biochem Pharmacol (1989) 0.77
N-(2,3-dimercaptopropyl)phthalamidic acid: protection, in vivo and in vitro, against arsenic intoxication. Toxicol Appl Pharmacol (1984) 0.77
Stereotyped flexion of forelimb and hindlimb to microstimulation of dentate nucleus in cebus monkeys. Brain Res (1976) 0.77
Utilization of renal slices to evaluate the efficacy of chelating agents for removing mercury from the kidney. Toxicology (1997) 0.77
Using motion perimetry to detect visual field defects in patients with idiopathic intracranial hypertension: a comparison with conventional automated perimetry. Neurology (1995) 0.76
Penicillamine and analogous chelating agents. Ann N Y Acad Sci (1971) 0.76
Lead chelates of meso- and racemic-dimercaptosuccinic acid. J Inorg Biochem (1989) 0.76
Exacerbation of parkinsonism by methyldopa. JAMA (1980) 0.76
Motor cortical neuronal activity patterns in monkeys performing several force tasks at the ankle. Brain Res (1984) 0.76
Synthesis and properties of the monomethyl ester of meso-dimercaptosuccinic acid and its chelates of lead (II), cadmium(II), and mercury(II). Chem Res Toxicol (1991) 0.76
Gene therapy systems: the need, experimental approach, and implications. Ann N Y Acad Sci (1971) 0.76
Experimental gene delivery systems for mammalian cells-the polyoma pseudovirus system. Adv Enzyme Regul (1978) 0.75
Evaluation of surgery for Parkinson's disease: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2000) 0.75
Health guides as influentials in central Buffalo. J Health Soc Behav (1976) 0.75
Polyoma pseudovirions: an experimental model for the development of DNA for gene therapy. Fed Proc (1972) 0.75
Cerebral hemodynamics and metabolism in postoperative cerebral vasospasm and treatment with hypertensive therapy. Ann Neurol (1981) 0.75
Postpolio syndrome--response to deprenyl (selegiline). Int J Neurosci (1993) 0.75
Assembly of a polyoma-like particle from empty capsids and DNA in a cell-free system. Adv Enzyme Regul (1980) 0.75
Transport and control of manganese ions in the central nervous system. Environ Res (1999) 0.75
Sequential cleavage of dinucleotides from DNA by SP3 DNase. 3. Substrate specificity and initiation of the hydrolysis from the 5-terminus of polynucleotides. J Mol Biol (1970) 0.75
Determination and metabolism of dithiol chelating agents. III. Formation of oxidized metabolites of 2,3-dimercaptopropane-1-sulfonic acid in rabbit. Drug Metab Dispos (1988) 0.75
Thymectomy in multiple sclerosis: a 3-year follow-up. Neurology (1985) 0.75
Optical isomers of 2,3-dimercapto-1-propanesulfonate: antidotal activity, in vitro and in vivo, against sodium arsenite. J Pharmacol Exp Ther (1983) 0.75